Nobody going after m2m except CYDY and the analyses of the data thus far are all pointing to a record homerun (homerun is already a given....what's left to determine is how far past we get).

Lucky CYDY shareholders have information that the general public doesn't have. We have more time to free up $$$ and get shares if SP doesn't react and stays range bound below $10. Easy $20+ when the PR gets out about efficacy of m2m trial, DSCM sneak peek findings/recommendations, uplist.